NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 pa...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/10/10/2362 |
| _version_ | 1797475061496545280 |
|---|---|
| author | Shih-Lung Cheng Chau-Chyun Sheu Chih-Feng Chian Jeng-Yuan Hsu Kuo-Chin Kao Liang-Wen Hang Ching-Hsiung Lin Wen-Feng Fang Hao-Chien Wang Diahn-Warng Perng |
| author_facet | Shih-Lung Cheng Chau-Chyun Sheu Chih-Feng Chian Jeng-Yuan Hsu Kuo-Chin Kao Liang-Wen Hang Ching-Hsiung Lin Wen-Feng Fang Hao-Chien Wang Diahn-Warng Perng |
| author_sort | Shih-Lung Cheng |
| collection | DOAJ |
| description | Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population. |
| first_indexed | 2024-03-09T20:39:44Z |
| format | Article |
| id | doaj.art-4ac3c4bd000247f78049b35a0f88ac43 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T20:39:44Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-4ac3c4bd000247f78049b35a0f88ac432023-11-23T23:01:48ZengMDPI AGBiomedicines2227-90592022-09-011010236210.3390/biomedicines10102362NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in TaiwanShih-Lung Cheng0Chau-Chyun Sheu1Chih-Feng Chian2Jeng-Yuan Hsu3Kuo-Chin Kao4Liang-Wen Hang5Ching-Hsiung Lin6Wen-Feng Fang7Hao-Chien Wang8Diahn-Warng Perng9Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan City 320, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, TaiwanDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, TaiwanDivision of Clinical Research, Taichung Veterans General Hospital, Taichung 407, TaiwanDepartment of Thoracic Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan 333, TaiwanDepartment of Pulmonary, China Medical University Hospital, Taichung 404, TaiwanInstitute of Genomics and Bioinformatics, National Chung Hsing University, Taichung 402, TaiwanDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Medicine, National Taiwan University Cancer Center, Taipei 100, TaiwanDepartment of Chest Medicine, School of Medicine, National Yang-Ming Chiao-Tung University, Taipei Veterans General Hospital, Taipei 112, TaiwanIdiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population.https://www.mdpi.com/2227-9059/10/10/2362nintedanibTaiwanidiopathic pulmonary fibrosislung functionreal-world registrypirfenidone |
| spellingShingle | Shih-Lung Cheng Chau-Chyun Sheu Chih-Feng Chian Jeng-Yuan Hsu Kuo-Chin Kao Liang-Wen Hang Ching-Hsiung Lin Wen-Feng Fang Hao-Chien Wang Diahn-Warng Perng NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan Biomedicines nintedanib Taiwan idiopathic pulmonary fibrosis lung function real-world registry pirfenidone |
| title | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
| title_full | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
| title_fullStr | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
| title_full_unstemmed | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
| title_short | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
| title_sort | nicefit a prospective non interventional and multicentric study for the management of idiopathic pulmonary fibrosis with antifibrotic therapy in taiwan |
| topic | nintedanib Taiwan idiopathic pulmonary fibrosis lung function real-world registry pirfenidone |
| url | https://www.mdpi.com/2227-9059/10/10/2362 |
| work_keys_str_mv | AT shihlungcheng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT chauchyunsheu nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT chihfengchian nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT jengyuanhsu nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT kuochinkao nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT liangwenhang nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT chinghsiunglin nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT wenfengfang nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT haochienwang nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT diahnwarngperng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan |